MedTrace Logo

Prediction of Systemic Thromboembolism and Bleeding in Atrial Fibrillation Patients With Factor Xa Inhibitor (Apixaban, Rivaroxaban) by Echocardiographic Parameters: Prospective Observational Study (AF-ECHO Study)

NCT06779695 · Status: ACTIVE_NOT_RECRUITING · Type: OBSERVATIONAL · Enrollment: 2000

Last updated 2025-01-16

No results posted yet for this study

Summary

Patients taking Factor Xa inhibitors (Apixaban, Rivaroxaban) in atrial fibrillation will be conducted a follow-up investigation on systemic embolism and bleeding events.

Conditions

  • Atrial Fibrillation (AF)

Sponsors & Collaborators

  • Korea University Ansan Hospital

    collaborator OTHER

  • Mediplex Sejong Hospital

    collaborator UNKNOWN

  • Chungnam National University Hospital

    collaborator OTHER

  • Chonnam National University Hospital

    collaborator OTHER

  • Kyung Hee University Hospital at Gangdong

    collaborator OTHER

  • Kyungpook National University Hospital

    collaborator OTHER

  • Korea University Guro Hospital

    collaborator OTHER

  • InjeUniversityIlsanPaikHospital

    collaborator UNKNOWN

  • Wonkwang University Hospital

    collaborator OTHER

  • Keimyung University Dongsan Medical Center

    collaborator OTHER

  • Korea University Anam Hospital

    lead OTHER

Principal Investigators

  • Mi-Na Kim, M.D., Ph.D. · Korea University Anam Hospital

  • Dong-Hyuk Cho, PhD · Korea University Anam Hospital

  • So Ree Kim, PhD · Korea University Anam Hospital

Eligibility

Min Age
19 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-04-21
Primary Completion
2028-09-30
Completion
2031-12-31

Countries

  • South Korea

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06779695 on ClinicalTrials.gov